Your browser doesn't support javascript.
loading
A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials.
Zhu, S; Wu, Z; Wang, W; Wei, L; Zhou, H.
Affiliation
  • Zhu S; Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Wu Z; Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Wang W; Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Wei L; School of Life Science, Anhui Medical University, Hefei, 230032, China. weilengyun@ahmu.edu.cn.
  • Zhou H; School of Life Science, Anhui Medical University, Hefei, 230032, China. hzhou@ahmu.edu.cn.
J Endocrinol Invest ; 47(4): 761-776, 2024 Apr.
Article in En | MEDLINE | ID: mdl-37839037
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease Limits: Humans Language: En Journal: J Endocrinol Invest Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Non-alcoholic Fatty Liver Disease Limits: Humans Language: En Journal: J Endocrinol Invest Year: 2024 Document type: Article Affiliation country: Country of publication: